Instituto Alexander Fleming BUENOS AIRES, Argentina
Learning Objectives:
SO-31: Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: an expanded dataset - Elena Garralda, et al
SO-32: Entrectinib in NTRK fusion-positive gastrointestinal cancers: updated integrated analysis - Ignacio Garrido-Laguna, et al
SO-33: Neoadjuvant immunotherapy in gastrointestinal tumors with mismatch repair deficiency: An institutional analysis - Sakti Chakrabarti, et al
